In April 2023, the puncture biopsy sample admitted to the Cancer Hospital Affiliated to FuDan University (China, Shanghai) for pathological consultation and was diagnosed with differentially differentiated cancer (testicular tumor) consistent with SMARCB1/INI-1 deletion. This evidence concerns the gene SMARCB1 and neoplasm of testis.